About: First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 11 April 2008

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) bài báo khoa học (vi) наукова стаття, опублікована у квітні 2008 (uk) scientific article published on 11 April 2008 (en) 2008 թվականի ապրիլի 11-ին հրատարակված գիտական հոդված (hy) artículu científicu espublizáu n'abril de 2008 (ast)
publication date	wds:Q81071045-DF2DA34B-C576-4DC1-9212-0BC40370D4FE
publication date	2008-04-11 00:00:00Z (xsd:dateTime)
author name string	wds:Q81071045-00AB5CE4-0D77-4076-B379-ECF4CF087AC7 wds:Q81071045-0786BDF3-B669-4088-B9BD-BDCC20E1E1A1 wds:Q81071045-166FC2CA-D956-4FA2-9266-AE048196C8A8 wds:Q81071045-51A3A330-F22C-41B8-B49E-2A6AAC32BBFE wds:Q81071045-5B80FE66-EA6B-4D8D-ADD0-4725677514EC wds:Q81071045-628F3B22-682D-4385-ACEF-4BC1C3B87CB2 wds:Q81071045-751FCCF7-468C-417C-BB9D-B5F602B7DAF2 wds:Q81071045-9308D3DF-B0F7-42A7-A7C4-33F303AC2F70 wds:Q81071045-98998036-B4B0-4EFE-89BF-65144D353DEB wds:Q81071045-D2C2E930-637C-4D74-AEE1-F7B5BA903F73 wds:Q81071045-D7F17CD7-1CBF-4571-84CA-7811ECA6D1B4 wds:Q81071045-E2EC4202-37C9-407E-A26A-7FFEB831FE2D
author name string	A Santoro B Escudier C Chevreau B Melichar S Bracarda J McKendrick S Négrier R Delva P Koralewski M Filipek P Pisa E Sevin
rdfs:label	First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma (en) First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma (nl)
skos:prefLabel	First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma (en) First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma (nl)
name	First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma (en) First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma (nl)
author	wds:Q81071045-09EFC0EB-4332-4503-BBF1-959A1E0850F9 wds:Q81071045-20682421-A66C-4E1E-9814-4AD24E5A8985 wds:Q81071045-89D18562-EC18-402E-BCB2-9A70560F54D7 wds:Q81071045-F637190B-0BA0-4DCE-9EA6-9B143C291C34
author	Alain Ravaud Armando Santoro Anna Pluzanska Cezary Szczylik
title	wds:Q81071045-AD9498DD-E750-4ECD-B5C1-0C21AE858A31
title	First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma (en)
page(s)	wds:Q81071045-58A5FD00-1664-490C-87F5-666D3722CCF2
page(s)	1470-1476
instance of	wds:Q81071045-D49B21B7-D258-4C38-8439-D8B750A7D0A3
instance of	scholarly article
main subject	wds:Q81071045-2C53FB70-D3B9-4E02-84D9-95C7F476FFB7 wds:Q81071045-BD214F04-BCD7-45D2-9288-5A19015793D4 wds:Q81071045-EBFE5CB4-CC09-48CD-BCF1-AEA31D9D1A4C
main subject	bevacizumab renal cell carcinoma metastatic renal cell carcinoma
PubMed ID	wds:Q81071045-625C7215-C4B4-4592-AAA9-8A24979DE390
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18408224
PubMed ID	18408224
published in	wds:Q81071045-7D0CB7E3-1F50-4EE3-9D6E-F83968162035
published in	Annals of Oncology
issue	wds:Q81071045-F1AB0D0E-8E2E-4294-AC8A-F2B876600C6D
volume	wds:Q81071045-01433582-2BB5-4C71-9319-83F802CF82C9
issue	8
volume	19
DOI	wds:Q81071045-A3218367-6481-424C-B4DA-E1E5C76A4FCD
DOI	http://dx.doi.org/10.1093/ANNONC/MDN161
DOI	10.1093/ANNONC/MDN161
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q81071045
is cites work of	Targeted therapy for advanced renal cell carcinoma Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma Tumor angiogenesis: insights and innovations Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib Molecular aspects of renal cell carcinoma: a review A survey of therapy for advanced renal cell carcinoma Bevacizumab: a review of its use in advanced cancer Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. Optimal management of renal cell carcinoma in the elderly: a review Targeted therapies in the management of renal cell carcinoma: role of bevacizumab Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies Antiangiogenic therapy in renal cell carcinoma: a plethora of choices The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials Targeted therapy in renal cancer Systemic therapy of metastatic renal cell carcinoma: from many options to the therapeutic strategy An update on targeted therapy in metastatic renal cell carcinoma Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis The bevacizumab experience in advanced renal cell carcinoma Immunotherapy for metastatic renal cell carcinoma Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'. Treatment of metastatic kidney cancer in elderly subjects

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software